Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study objectives to assess the role of endothelial monocyte-activating polypeptide II
(EMAP II) as a marker of endothelial dysfunction and disturbed angiogenesis in sickle cell
disease and to identify its correlation With the oxidative status.
Phase:
Phase 4
Details
Lead Sponsor:
Ain Shams University
Treatments:
alpha-Tocopherol Antioxidants Small inducible cytokine subfamily E, member 1 Tocopherols Tocotrienols Vitamin E Vitamins